Bifogade filer
AB Rapport 2023 Q2 Eng
Kurs & Likviditet
Prenumeration
Kalender
| 2025-05-08 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | Bokslutskommuniké 2024 |
| 2024-11-07 | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | Ordinarie utdelning ACTI 0.00 SEK |
| 2024-05-22 | Årsstämma 2024 |
| 2024-05-08 | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | Bokslutskommuniké 2023 |
| 2023-11-09 | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | Ordinarie utdelning ACTI 0.00 SEK |
| 2023-05-24 | Årsstämma 2023 |
| 2023-05-04 | Kvartalsrapport 2023-Q1 |
| 2023-02-09 | Bokslutskommuniké 2022 |
| 2022-11-03 | Kvartalsrapport 2022-Q3 |
| 2022-08-04 | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2022-05-19 | Årsstämma 2022 |
| 2022-04-21 | Kvartalsrapport 2022-Q1 |
| 2022-02-09 | Bokslutskommuniké 2021 |
| 2021-11-04 | Kvartalsrapport 2021-Q3 |
| 2021-08-05 | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2021-05-19 | Årsstämma 2021 |
| 2021-04-22 | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | Bokslutskommuniké 2020 |
| 2020-11-30 | Extra Bolagsstämma 2020 |
| 2020-11-05 | Kvartalsrapport 2020-Q3 |
| 2020-08-06 | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2020-05-19 | Årsstämma 2020 |
| 2020-04-23 | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | Bokslutskommuniké 2019 |
| 2019-11-14 | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | Ordinarie utdelning ACTI 0.00 SEK |
| 2019-05-23 | Årsstämma 2019 |
| 2019-04-25 | Kvartalsrapport 2019-Q1 |
| 2019-04-04 | Extra Bolagsstämma 2019 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-15 | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | Ordinarie utdelning ACTI 0.00 SEK |
| 2018-05-17 | Årsstämma 2018 |
| 2018-04-26 | Kvartalsrapport 2018-Q1 |
| 2018-03-19 | Extra Bolagsstämma 2018 |
| 2018-02-15 | Bokslutskommuniké 2017 |
| 2017-11-09 | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | Kvartalsrapport 2017-Q2 |
| 2017-06-15 | Årsstämma 2017 |
| 2017-04-27 | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | Bokslutskommuniké 2016 |
| 2016-11-11 | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | Ordinarie utdelning ACTI 0.00 SEK |
| 2016-05-26 | Årsstämma 2016 |
| 2016-04-28 | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | Bokslutskommuniké 2015 |
| 2015-11-06 | Kvartalsrapport 2015-Q3 |
| 2015-06-12 | Ordinarie utdelning ACTI 0.00 SEK |
| 2015-06-11 | Årsstämma 2015 |
| 2015-04-23 | Kvartalsrapport 2015-Q1 |
| 2015-02-11 | Bokslutskommuniké 2014 |
| 2014-12-01 | Extra Bolagsstämma 2014 |
| 2014-11-05 | Kvartalsrapport 2014-Q3 |
| 2014-08-07 | Kvartalsrapport 2015-Q2 |
| 2014-05-16 | Ordinarie utdelning ACTI 0.00 SEK |
| 2014-05-15 | Årsstämma 2014 |
| 2014-04-24 | Kvartalsrapport 2014-Q1 |
| 2014-02-13 | Bokslutskommuniké 2013 |
| 2014-01-16 | 15-7 2014 |
| 2013-11-07 | Kvartalsrapport 2013-Q3 |
| 2013-08-07 | Kvartalsrapport 2013-Q2 |
| 2013-05-16 | Ordinarie utdelning ACTI 0.00 SEK |
| 2013-05-15 | Årsstämma 2013 |
| 2013-04-25 | Kvartalsrapport 2013-Q1 |
| 2013-02-14 | Bokslutskommuniké 2012 |
| 2013-01-10 | 15-6 2013 |
| 2012-11-09 | Kvartalsrapport 2012-Q3 |
| 2012-09-11 | Extra Bolagsstämma 2012 |
| 2012-08-10 | Kvartalsrapport 2012-Q2 |
| 2012-06-14 | Kapitalmarknadsdag 2012 |
| 2012-05-11 | Ordinarie utdelning ACTI 0.00 SEK |
| 2012-05-10 | Årsstämma 2012 |
| 2012-04-26 | Kvartalsrapport 2012-Q1 |
| 2012-02-16 | Bokslutskommuniké 2011 |
| 2012-01-12 | 15-7 2012 |
| 2011-11-03 | Kvartalsrapport 2011-Q3 |
| 2011-08-11 | Kvartalsrapport 2011-Q2 |
| 2011-05-06 | Ordinarie utdelning ACTI 0.00 SEK |
| 2011-05-05 | Årsstämma 2011 |
| 2011-04-28 | Kvartalsrapport 2011-Q1 |
| 2011-02-10 | Bokslutskommuniké 2010 |
| 2010-10-27 | Kvartalsrapport 2010-Q3 |
| 2010-08-11 | Kvartalsrapport 2010-Q2 |
| 2010-05-07 | Ordinarie utdelning ACTI 0.00 SEK |
| 2010-05-06 | Årsstämma 2010 |
| 2010-04-22 | Kvartalsrapport 2010-Q1 |
| 2010-02-11 | Bokslutskommuniké 2009 |
| 2009-11-05 | Kvartalsrapport 2009-Q3 |
| 2009-08-06 | Kvartalsrapport 2009-Q2 |
| 2009-05-08 | Ordinarie utdelning ACTI 0.00 SEK |
| 2009-05-07 | Årsstämma 1 |
| 2009-04-23 | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SECOND QUARTER IN BRIEF
- Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
- Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26)
- Positive safety and tolerability in clinical phase I study and preclinical ocular biodistribution data supporting the further development of laquinimod eye drops for inflammatory eye diseases were established (May 30)
- New preclinical data regarding tasquinimod's anti-fibrotic effects in myelofibrosis were presented at EHA 2023 (June 10)
EVENTS AFTER THE END OF THE PERIOD
- Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
- As communicated previously in the Q1, 2023 Interim Report, various sources of future financing are being explored, including partnering the company’s development programs, directed share issues to new investors, rights issue to current investors as well as other types of financing alternatives. These explorations remain ongoing. To secure the continued operations of Active Biotech, two major shareholders have provided a financing commitment to the Company of approximately 20 MSEK, to enable the time necessary to conclude on the ongoing opportunities being explored
FINANCIAL SUMMARY
| SEK M | Apr-Jun | Jan-Jun | Full-year | ||
| 2023 2022 | 2023 2022 | 2022 | |||
| Net sales | - | - | - | ||
| Operating profit/loss | -11.3 | -14.0 | -23.1 | -29.3 | -57.9 |
| Profit/loss after tax | -11.2 | -14.3 | -22.7 | -30.0 | -58.4 |
| Earnings per share (SEK) | -0.04 | -0.07 | -0.09 | -0.14 | -0.25 |
| Cash and cash equivalents (at close of period) | 15.7 | 21.9 | 41.8 | ||
The report is also available at www.activebiotech.com
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-24 08:30 CEST.